These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 15996700)

  • 1. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
    Snow ET; Sykora P; Durham TR; Klein CB
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of DNA polymerase beta-dependent base excision repair in cultured human cells after low dose exposure to arsenite.
    Sykora P; Snow ET
    Toxicol Appl Pharmacol; 2008 May; 228(3):385-94. PubMed ID: 18252256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
    Kitchin KT; Conolly R
    Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of arsenic genotoxicity for dose response of carcinogenic effects.
    Rudel R; Slayton TM; Beck BD
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):87-105. PubMed ID: 8661328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic toxicity at low doses: epidemiological and mode of action considerations.
    Schoen A; Beck B; Sharma R; Dubé E
    Toxicol Appl Pharmacol; 2004 Aug; 198(3):253-67. PubMed ID: 15276404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites.
    Kitchin KT
    Toxicol Appl Pharmacol; 2001 May; 172(3):249-61. PubMed ID: 11312654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic changes induced by chronic low dose exposure to arsenic of mouse testicular Leydig cells.
    Singh KP; DuMond JW
    Int J Oncol; 2007 Jan; 30(1):253-60. PubMed ID: 17143536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic carcinogenesis in the skin.
    Yu HS; Liao WT; Chai CY
    J Biomed Sci; 2006 Sep; 13(5):657-66. PubMed ID: 16807664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of selenium and arsenic on oxidative stress, DNA oxidative damage and repair in HepG2 cells].
    Lai R; Wang Y; Li X; Yu RA
    Wei Sheng Yan Jiu; 2008 Nov; 37(6):645-8. PubMed ID: 19238993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of responses to dimethylarsinic acid in female F344 rat urothelium.
    Sen B; Wang A; Hester SD; Robertson JL; Wolf DC
    Toxicology; 2005 Nov; 215(3):214-26. PubMed ID: 16122865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormesis and dose-response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens.
    Fukushima S; Kinoshita A; Puatanachokchai R; Kushida M; Wanibuchi H; Morimura K
    Carcinogenesis; 2005 Nov; 26(11):1835-45. PubMed ID: 15975961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity.
    Gentry PR; McDonald TB; Sullivan DE; Shipp AM; Yager JW; Clewell HJ
    Environ Mol Mutagen; 2010 Jan; 51(1):1-14. PubMed ID: 19551812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis of BEAS-2B cells exposed to trivalent arsenicals and dimethylthioarsinic acid.
    Chilakapati J; Wallace K; Ren H; Fricke M; Bailey K; Ward W; Creed J; Kitchin K
    Toxicology; 2010 Jan; 268(1-2):31-9. PubMed ID: 19945496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of oxidative stress in hormesis induced by sodium arsenite in human embryo lung fibroblast (HELF) cellular proliferation model.
    Yang P; He XQ; Peng L; Li AP; Wang XR; Zhou JW; Liu QZ
    J Toxicol Environ Health A; 2007 Jun; 70(11):976-83. PubMed ID: 17479414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative investigations of sodium arsenite, arsenic trioxide and cadmium sulphate in combination with gamma-radiation on apoptosis, micronuclei induction and DNA damage in a human lymphoblastoid cell line.
    Hornhardt S; Gomolka M; Walsh L; Jung T
    Mutat Res; 2006 Aug; 600(1-2):165-76. PubMed ID: 16764896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic-induced bladder cancer in an animal model.
    Cohen SM; Ohnishi T; Arnold LL; Le XC
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.